Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 25, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated U.S. net product revenues of $18.4 million for SYFOVRE™ (pegcetacoplan injection) and $20.4 million for EMPAVELI® (pegcetacoplan) SYFOVRE launched in the U.S. as the first and only treatment...
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
April 27, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
April 23, 2023 18:05 ET
|
Apellis Pharmaceuticals, Inc.
Showed visual function and quality-of-life benefits in patients with extrafoveal lesionsSlowed the loss of retinal pigmented epithelial and photoreceptor cells, both of which are required for visual...
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
April 21, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024 WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) --...
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
April 17, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
GA is an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...